Codon

SEPTEMBER 29, 2024

Partially as a marketing stunt and partially to save money, several companies opted to do no further testing before phase I trials after the approval of their internal models. On the surface, they hadn't deviated much from the early 2020s: a virus infected a cell and released the genetic therapy hidden within.

Engineering 137

Engineering Virus DNA Therapies 137

The Pharma Data

SEPTEMBER 14, 2020

Prof Martin Landray from the University of Oxford, who is co-leading the Recovery Trial, said: “This is the first type of treatment that’s targeted for this specific virus. Antibodies could be described as the “warriors” of the immune system. This is then given to patients, immediately boosting their immune response.

Trials 52

Trials Immune Response Virus Vaccine 52

The Pharma Data

DECEMBER 20, 2020

BT-001 is a best-in-class oncolytic Vaccinia virus. platform and its patented large-capacity VV cop TK-RR- oncolytic virus, which has been engineered to encode both a Treg-depleting human recombinant anti-CTLA4 antibody generated by BioInvent’s proprietary n-CoDeR ® /F.I.R.S.T LUND, Sweden and STRASBOURG, France , Dec.

Virus 40

Virus Trials Clinical Trials Clinical Development 40

Drug Target Review

FEBRUARY 7, 2024

We had built a machine learning classifier that has been trained to identify amino acid sequences that have the potential to mimic ‘host defense peptides’ from the human innate immune system. Such peptides play a critical role in the machinery for amplifying innate immune responses. This work can potentially help with that also.

RNA 69

RNA Virus Immune Response Engineering 69

Codon

FEBRUARY 13, 2024

doi: 10.2210/rcsb_pdb/goodsell-gallery-048 The Virus that Cures It’s been over 25 years since the science magazine Discover first ran an extraordinary article about how a long-forgotten medical treatment, used in the former Soviet country of Georgia, could save us from the growing threat of untreatable, drug-resistant infections.

Therapies 124

Therapies Virus DNA Clinical Trials 124

The Pharma Data

JUNE 30, 2021

For their remarkable scientific contributions, doctoral student Julia Klaus, Zurich University VetSuisse Faculty, and Dr Yasmin Parr from the MRC-University of Glasgow, Centre for Virus Research, have received the 2021 ABCD Young Scientist Award.

Immune Response 52

Immune Response Virus Disease Doctors 52

Drug Target Review

JULY 7, 2023

Antibodies protect us by attaching to molecules on those invaders (known as antigens) and triggering our body’s natural immune response to destroy them. This can create an abnormal immune response that attacks the cells of our bodies and contributes to the development of autoantibody diseases. MDedge ObGyn.

Disease 98

Disease Immune Response Therapies Treatment 98

Codon

AUGUST 27, 2024

While reading all the sequences present in a sample, researchers want to find any that are out of place, such as those that belong to a never-before-seen virus. This cleaning, annotation, and characterization work is all performed computationally.

DNA 93

DNA Laboratories Hospitals Virus 93

The Pharma Data

JUNE 25, 2021

The outcome confirms that only one single case was attributable to the original SARS-CoV-2 virus. “In addition, the variant-rich environment underlines the importance of developing next-generation vaccines as new virus variants continue to emerge.” More than half of the cases (57%) were caused by Variants of Concern.

Vaccine 52

Vaccine Trials Immune Response Virus 52

NIH Director's Blog: Drug Development

MARCH 18, 2021

Yet they are the source for many of the viruses that have spilled over into humans with devastating effect, including rabies, Ebola virus, Nipah and Hendra viruses, severe acute respiratory syndrome coronavirus (SARS-CoV), and, likely, SARS-CoV-2. Despite carrying all of these viruses, bats rarely show symptoms of being sick.

Virus 52

Virus Immune Response Clinical Trials Treatment 52

Drug Target Review

SEPTEMBER 8, 2023

Enabling T cells to respond to threats To grasp the significance of this discovery, it’s useful to envision the internal layout of a T cell. Cheroutre remarks, “The TCR signalosome plays an immensely important role in facilitating communication between a cell’s external and internal environments.”

Regulations 98

Regulations Research DNA Immune Response 98

NIH Director's Blog: Drug Development

OCTOBER 27, 2020

Another promising strategy is drugs that target the proteins within human cells that the virus needs to infect, multiply, and spread. These studies narrowed the list to 73 human proteins that the virus depends on to replicate. Food and Drug Administration to treat COVID-19.

Drug Development 52

Drug Development Drugs Virus Science 52

NIH Director's Blog: Drug Development

MAY 21, 2020

B38 blocks SARS-CoV-2 from binding to the ACE2 receptor (light pink) of a human cell, ACE2 is what the virus uses to infect cells. References : [1] Humoral immune response and prolonged PCR positivity in a cohort of 1343 SARS-CoV 2 patients in the New York City region. In the U.S. medRxiv.

Virus 52

Virus Vaccine Laboratories Small Molecule 52

The Pharma Data

SEPTEMBER 17, 2020

The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus. The majority of current candidate vaccines aim to induce an antibody response against the spike protein. The test targets antibodies against the spike protein.

Vaccine 52

Vaccine Virus Clinical Trials Immune Response 52

The Pharma Data

AUGUST 22, 2021

Many of the elderly patients who survived the virus were poor: not exactly the demographic you would expect to fare well in a health crisis. One of the most dangerous phenomena COVID-19 can trigger in your body is something called a cytokine storm, which is a potentially fatal amplification of an immune response.

Doctors 52

Doctors Drugs Immune Response Virus 52

The Pharma Data

DECEMBER 31, 2020

Researchers at Stanford Medicine found that COVID-19 antibodies preferentially target different parts of the SARS-CoV-2 virus in mild COVID-19 cases than they do in severe cases. The spike protein binds to the ACE2 receptor on human cells, which allows the virus to enter the cell. What’s Going on in the International Space Station?

Research 52

Research Virus Immune Response Cell Biology 52

Codon

DECEMBER 12, 2024

It would also be undetectable by key parts of the human immune system. Some scientists even think it had a virus defense system; “researchers say LUCA likely housed 19 CRISPR genes, which bacteria use to slice up viral threats,” reports Quanta Magazine. Not all pathogens spread quickly.

DNA 102

DNA RNA Vaccine Virus 102

The Pharma Data

OCTOBER 22, 2020

The twenty-sixth meeting of the Emergency Committee under the International Health Regulations (2005) (IHR) on the international spread of poliovirus was convened and opened by the WHO Deputy Director-General on 14 October 2020 with committee members attending via video conference, supported by the WHO Secretariat.

Vaccine 52

Vaccine International Immune Response Virus 52

The Pharma Data

JANUARY 5, 2021

Food and Drug Administration said Monday that any American who gets the Moderna or Pfizer coronavirus vaccines must get two full doses, despite international debate on possible ways to stretch vaccine supply. But a faster-spreading virus could swamp hospitals with seriously ill patients. TUESDAY, Jan.

Vaccine 52

Vaccine FDA Virus Immune Response 52

Vial

DECEMBER 11, 2023

Hepatitis C virus (HCV) infection is a global health problem with complications that place a significant economic burden on national health systems. Other inhibitors, currently in different stages of development (including clinical trials ), mainly target viral non-structural proteins or the internal ribosome entry site (IRES).

Clinical Research 52

Clinical Research Therapies Research Vaccine 52

The Pharma Data

SEPTEMBER 7, 2021

Bristol Myers Squibb has a global exclusive license to develop, manufacture and commercialize the Rockefeller University’s novel monoclonal antibody (“mAb”) duo treatment that neutralizes the SARS-CoV-2 virus for therapy or prevention of COVID-19. We are encouraged that more than 85% of our employees in the U.S.

Clinical Trials 52

Clinical Trials Vaccine Virus Trials 52

The Pharma Data

MARCH 16, 2021

The cobas SARS-CoV-2 Variant Set 1 Test is designed to detect key spike mutations in virus variants associated with increased human-to-human transmission. Among them, mutations E484K, N501Y and del 69-70 are located in the spike protein, the region that enables the virus to attach to and enter the human cell. 2,3 Another variant, B.1.351,

Clinical Trials 52

Clinical Trials Laboratories Virus Vaccine 52

The Pharma Data

JANUARY 31, 2021

Gritstone’s vaccine technology has the potential to educate the immune system to specifically recognize and destroy HIV-infected cells by leveraging SAM and adenoviral vectors. This press release features multimedia. View the full release here: [link].

Vaccine 52

Vaccine Science Clinical Trials Licensing 52

The Pharma Data

NOVEMBER 18, 2020

Through university collaboration agreements the company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body by studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses with the goal of improving human wellbeing.

Immune Response 40

Immune Response FDA Production Regulations 40

The Pharma Data

OCTOBER 20, 2020

Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, announced results from an independent laboratory validating internal animal studies showing the ability of Annamycin to target lung localized tumors.

Clinical Trials 40

Clinical Trials Pharmaceutical Companies Treatment Immune Response 40

The Pharma Data

DECEMBER 15, 2020

The condition affects the skin and internal organs and is driven by inflammation and fibrosis, which can lead to severe damage and failure of several multiple body organs. CUE-300 Series Immuno-STATs may offer autoimmune patients therapeutic benefits without compromising their immune systems.

Disease 52

Disease Clinical Trials Small Molecule Trials 52

PLOS: DNA Science

JANUARY 4, 2024

The microbes deploy them to dismantle the genetic material of infecting viruses, a little like an immune response. .” CRISPRs are short DNA sequences, peppered with repeats, that latch onto DNA-cutting enzymes, commandeering and directing them to snip certain parts of a chromosome.

FDA Approval 52

FDA Approval DNA Therapies Clinical Trials 52

The Pharma Data

NOVEMBER 29, 2020

To access the conference call, please dial +1 877 870 9135 (from the US) or +44 2071 928338 (international) and refer to conference ID 4469307. 3 The majority of CMV infections are not serious, and the virus can lay dormant in the body for years. Both technologies enable repeat administration to augment and refresh immune responses.

Vaccine 40

Vaccine Clinical Trials Disease Therapies 40

Codon

JULY 27, 2023

a lower risk of immune responses. reports Cas9 proteins that can penetrate into the central nervous system without being packaged into an adeno-associated virus, all while causing a lower immune response than a prior version of the same technology. ” The tool was crafted with a virus, called GIL16.

Therapies 52

Therapies RNA DNA Engineering 52

Codon

JULY 27, 2023

a lower risk of immune responses. reports Cas9 proteins that can penetrate into the central nervous system without being packaged into an adeno-associated virus, all while causing a lower immune response than a prior version of the same technology. ” The tool was crafted with a virus, called GIL16.

Therapies 52

Therapies RNA DNA Engineering 52

The Pharma Data

SEPTEMBER 15, 2020

Based on the acceptable safety profile and the favorable immune response data, including the 4th dose response data, Pfizer received Breakthrough Therapy Designation. An update on Pfizer’s potential first-in-class maternal vaccine candidate for the prevention of respiratory syncytial virus (RSVpreF). Internal Medicine.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52

The Pharma Data

NOVEMBER 1, 2020

The scientific concept, to activate nasal mucosal immunity by nasally administered Foralumab, is to fight against the virus in the respiratory tract and lungs,” stated Dr. Shailubhai, CEO and CSO of Tiziana Life Sciences. Thus, our clinical study is both timely and potentially a life changer for the COVID-19 patients.

Clinical Trials 40

Clinical Trials Trials Medical Schools Hospitals 40

The Pharma Data

APRIL 27, 2021

up 60%) driven by increase disease and product awareness as well as adoption of new ISTH (International Society on Thrombosis and Haemostasis) TTP guidelines. MRT5500 (SP0254), an mRNA vaccine candidate against SARS-CoV-2, entered Phase 1/2 to assess safety, immune response and reactogenicity.

Vaccine 52

Vaccine Production FDA Disease 52

The Pharma Data

NOVEMBER 10, 2021

Next generation vaccines for COVID-19 should aim to induce an immune response against ‘replication proteins’, essential for the very earliest stages of the viral cycle, concludes new research carried out by UCL scientists. ” Discovering the T cell response to replication proteins.

Vaccine 52

Vaccine Immune Response Virus International 52

The Pharma Data

NOVEMBER 9, 2020

Specifically, tezepelumab targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic and other types of airway inflammation associated with severe asthma. J Intern Med 2012;272:121–32. 6 Kupczyk M, Wenzel S.

Trials 52

Trials Production Clinical Trials Government 52

The Pharma Data

SEPTEMBER 5, 2021

” These findings were presented at the European Respiratory Society (ERS) International Congress 2021 between September 5-8. TSLP is released in response to multiple triggers associated with asthma exacerbations, including allergens, viruses and other airborne particles.

Trials 52

Trials Clinical Trials Therapies Treatment 52

The Pharma Data

JULY 8, 2021

Specifically, tezepelumab targets and blocks thymic stromal lymphopoietin (TSLP), a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic and other types of airway inflammation associated with severe asthma.(24,25). 2016;116:37-42.

FDA 52

FDA Trials Therapies Treatment 52